1.. Introduction
================

Osteosarcoma is a malignant tumor of mesenchymal origin and primarily occurs in children, adolescents, and young adults. This pleiomorphic tumor of the bone, based on animal model systems ([@b1-or-38-02-0625]), depends on new blood vessel development, also known as angiogenesis, for tumor growth and metastasis. Although modern multimodality treatment has significantly improved tumor resectability and the long-term outcome of these patients, 25--35% of patients with initially non-metastatic disease subsequently develop metastasis and this remains the major cause of death ([@b2-or-38-02-0625]). At the same time, axial skeletal osteosarcoma preliminarily responds poorly to chemotherapy and has been proven to have an even more dismal prognosis ([@b3-or-38-02-0625]). From the review of van Maldegem *et al* ([@b2-or-38-02-0625]) and Lagmay *et al* ([@b4-or-38-02-0625]), we concluded that in the past two decades, published phase I/II clinical trials on chemotherapy for osteosarcoma failed to make significant progress in refractory cases. With the study of oncogenesis and pathobiological behavior of osteosarcoma ([@b1-or-38-02-0625]), we know that new blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination.

Several groups have evaluated tumor micro-vessel density and outcome in osteosarcoma ([@b5-or-38-02-0625]--[@b7-or-38-02-0625]). Expression of VEGF has been suggested as a means of evaluating the prognostic importance of angiogenesis in osteosarcoma ([@b8-or-38-02-0625]). Monotherapy with second-generation broad-spectrum VEGF receptor tyrosine kinase inhibitors (TKIs) in sarcoma has now become an area of active research and application beyond gastrointestinal stromal tumors (GISTs). Within all of those preclinical experiments and clinical trials ([@b6-or-38-02-0625], [@b9-or-38-02-0625]--[@b13-or-38-02-0625]), the milestone of the treatment on advanced osteosarcoma should count on the application of anti-angiogenesis TKIs sorafenib on refractory cases from the Italian Sarcoma Group ([@b13-or-38-02-0625]), which officially raised the 4-month progression-free survival (PFS) from \<30--46% for the first time. However, things had seemed not to change as dramatically as was expected since then. The main hurdle that researchers need to get over should be sensitivity and drug-resistance ([@b14-or-38-02-0625]).

The goals of this review are: a) to review representative agents in *in vitro* and *in vivo* experiments that showed promise for osteosarcoma based on anti-angiogenesis therapy; b) to summarize the current phase I and II trials of anti-angiogenensis therapies that have been explored in advanced osteosarcoma patients; and c) to focus on targeting the action towards VEGFR and to discuss current hurdles and future perspectives.

2.. Tumor angiogenesis and anti-angiogenesis therapy in osteosarcoma
====================================================================

### Tumor angiogenesis and optional treatments

Angiogenesis is the process of new blood vessel development, which is critical in both physiological development and pathological processes, such as tumor progression, wound healing, and cardiovascular, inflammatory, ischemic, and infectious diseases ([@b15-or-38-02-0625]). In response to hypoxia, tumor tissues produce and release angiogenic growth factors, such as vasculo-endothelial growth factor (VEGF), the acidic and basic fibroblast growth factors (aFGF and bFGF), and the platelet-derived endothelial cell growth factor (PD-ECGF) to recruit new blood vessels by angiogenesis and vasculogenesis ([@b16-or-38-02-0625]). It is now widely accepted that both mutations of oncogenes and tumor suppressor genes lead to the switch into an angiogenic tumor. According to Gorlick *et al* ([@b1-or-38-02-0625]), osteosarcoma has complex unbalanced karotypes and with alterations of the p53 and retinoblastoma pathways in most cases, thus the vasculature playing an intimate role in the progression of the pathologic development of osteosarcoma.

VEGF is a key tumor-derived angiogenic factor that has multiple functions, including stimulation of angiogenesis, vasculogenesis, inflammation, and vascular permeability, which constitutes the most important signaling pathways in tumor angiogenesis ([@b7-or-38-02-0625]). According to Niu *et al* ([@b16-or-38-02-0625]), the whole VEGF family has been identified to comprise 8 members with a common VEGF homology domain: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placenta growth factor (PIGF)-1 and −2. As shown in [Fig. 1](#f1-or-38-02-0625){ref-type="fig"}, VEGFs signal through 3 tyrosine kinase receptors, known as Flt-1 (VEGFR-1), Flk-1/KDR (VEGFR-2), and VEGFR-3 ([@b17-or-38-02-0625]), which were previously thought to be predominantly expressed by endothelial cells, but in actual fact are also in sarcoma cell lines with limited study ([@b18-or-38-02-0625]--[@b21-or-38-02-0625]). It has been reported that both VEGFR-1 and −2 can promote angiogenesis and VEGFR-3 stimulation leads to lymphangiogenesis ([@b22-or-38-02-0625]).

There is a general consensus that VEGFR-2 is the dominant receptor in mediating the pro-angiogenic functions of VEGF-A and this pathway has been prioritized for the development of antiangiogenic therapies ([@b16-or-38-02-0625], [@b23-or-38-02-0625]). Though VEGFR-1 has a 10-fold higher binding affinity for VEGF-A, its activation has less impact on the activation of intracellular signaling intermediates than VEGFR-2 ([@b23-or-38-02-0625]).

Recognition of the VEGF pathway as a key regulator of angiogenesis has led to the development of several VEGF-targeted agents, including agents that prevent VEGF-A binding to its receptors ([@b24-or-38-02-0625]), antibodies that directly block VEGFR-2 ([@b25-or-38-02-0625]), and small molecules that inhibit the kinase activity of VEGFR-2 thereby block growth factor signaling ([@b26-or-38-02-0625]). Some of them have been approved by the FDA of the US for clinical applications ([@b16-or-38-02-0625]). Previous representative anti-angiogenic compounds ([@b10-or-38-02-0625],[@b27-or-38-02-0625]--[@b39-or-38-02-0625]) are summarized in [Table I](#tI-or-38-02-0625){ref-type="table"} with median inhibition concentration (IC~50~) noted for comparison.

Moreover, Broadhead *et al* ([@b40-or-38-02-0625]--[@b43-or-38-02-0625]) repeatedly reported that pigment epithelium-derived factor (PEDF), co-localized with VEGF in tumor tissue, was probably important in the fine-tuning of tumor vasculature and aggression. However, the clinical application of this agent is under investigation (NCT00702494).

### Fundamental study of angiogenesis in osteosarcoma and other related cellular signaling pathways

Geller and Gorlick ([@b44-or-38-02-0625]) reviewed HER-2 targeted treatment of osteosarcoma. The results showed that HER-2 expression as a prognostic factor in osteosarcoma remained controversial and a comparison of the results is difficult because of variables, including the handling and preparation of material, tissue heterogeneity, fixation techniques, storage conditions, antibody characteristics, scoring scheme, and staining interpretation due to single-institution, retrospective studies that were limited in size. Abdeen *et al* ([@b45-or-38-02-0625]) stated in 2009 that there was a negative correlation between VEGFR-3 and both overall survival and event-free survival of osteosarcoma, and VEGF-B was correlated with a poor histologic response to chemotherapy. In 2011, Yang *et al* ([@b46-or-38-02-0625]) reported that vascular endothelial growth factor (VEGF) pathway genes collectively were amplified, and alterations of this pathway were validated by fluorescence *in situ* hybridization (FISH) and immunohistochemistry analyses in 58 formalin-fixed, paraffin-embedded osteosarcoma archival tissues that had clinical follow-up information. Lammli *et al* ([@b47-or-38-02-0625]) in 2012 demonstrated that there was a significant positive correlation between VEGF expression and tumor stages among these cases (P\<0.01). The data also suggested a higher cancer recurrence and more frequent cases of remote metastasis in the high-VEGF group compared to the low-VEGF group. The expression of VEGF has been used as a more objective means of evaluating the prognostic importance of angiogenesis in osteosarcoma. One group found that 63% of osteosarcoma samples demonstrated VEGF immunohistochemical staining in tumor cells ([@b8-or-38-02-0625]).

In 2013, Chen *et al* ([@b48-or-38-02-0625]) completed a meta-analysis of published studies and performed a systematic review to provide a comprehensive assessment of the prognostic role of VEGF expression. They included 12 studies with a total of 559 osteosarcoma patients in the systematic review and meta-analysis. Compared with osteosarcoma patients with low or negative VEGF expression, patients with high VEGF expression were obviously associated with lower disease-free survival (OR=0.25, 95% CI 0.11--0.58, P=0.001, I^2^=56.4%). In addition, patients with high VEGF expression were obviously associated with lower overall survival (OR=0.22, 95% CI 0.13--0.35, P\<0.001, I^2^=0.0 %). Therefore, the findings from this systematic review suggested that VEGF expression was an effective biomarker of prognosis in patients with osteosarcoma. However, different from soft tissue sarcoma ([@b49-or-38-02-0625]), osteosarcoma has not been classified by which subtypes of VEGFR expression correlate with prognosis. Kampmann *et al* ([@b49-or-38-02-0625]) reported in 2015 that the high expression of VEGFR1-3 and PDGFR-β was significantly correlated with higher grading (G2 vs. G3, P\<0.05), and high VEGFR-2 was significantly correlated with decreased patient survival (P\<0.001).

According to Aurby *et al* ([@b50-or-38-02-0625]), angiogenesis inhibitors can be divided into 2 classes: direct inhibitors and indirect inhibitors. Direct inhibitors target endothelial cells by arresting proliferation and migration of these cells or by inducing their apoptosis. Indirect angiogenesis inhibitors act on the signaling pathways induced by angiogenic stimuli, by sequestering the angiogenic factors secreted by tumor cells, or by blocking the signal transduction pathways that are activated when binding factors meet their receptors on endothelial cells. The first direct inhibitor was endostatin, which was an internal fragment of the carboxy-terminus of collagen XVIII ([@b51-or-38-02-0625]). It is a paradigm of a broad-spectrum endogenous anti-angiogenic molecule, through which the results of *in vitro* experiments are satisfactory. However, methods of resolubilization gave very low yields of active proteins, which makes it hard to be a mature pharmaceutical and obstructs its further development. Bevacizumab ([@b52-or-38-02-0625]) neutralizes all isoforms of human VEGF and inhibits VEGF-induced proliferation of endothelial cells *in vitro* with an ED~50~ of approximately 50 ng/ml. It was tested in combination with several chemotherapeutic drugs, such as doxorubicin, topotecan, paclitaxel, and docetaxel, showing an additive antitumor effect ([@b28-or-38-02-0625],[@b53-or-38-02-0625],[@b54-or-38-02-0625]). However, as for osteosarcoma, clinical application did not prove as effective as the experiments ([@b53-or-38-02-0625]). With innovation from the VEGF-A aptamer ([@b55-or-38-02-0625]) to VEGF trap ([@b56-or-38-02-0625]), more focus has been given to the VEGFR tyrosine kinase inhibitors (TKIs) ([@b7-or-38-02-0625],[@b16-or-38-02-0625]).

Protein kinases are key enzymes in the regulation of various cellular processes that catalyse transfer of a phosphate group from ATP to a hydroxyl group of a serine or a threonine. Among the 90 identified genes encoding proteins with tyrosine kinase activity, 58 encode receptors divided into 20 subfamilies ([@b57-or-38-02-0625]). Of these, EGFR/ErbB (class I), the receptor for insulin (class II), PDGF (class III), FGF (class IV), VEGF (class V), and HGF (MET, class VI) are strongly associated with oncological diseases ([@b58-or-38-02-0625]). Unlike bevacizumab, VEGF Trap, and pegaptanib, which target extracellular VEGF, TKIs target the intracellular signaling pathways of VEGF receptors as well as a variety of receptors that rely on a tyrosine kinase component to function properly, including PDGF receptor, FMS-like tyrosine kinase 3 (FLT3), RAF, and c-KIT receptors ([@b16-or-38-02-0625]). In [Table I](#tI-or-38-02-0625){ref-type="table"}, we summarize the classic TKIs compounds in preclinical experiments for osteosarcoma and their main targeted region. Sunitinib and sorafenib share a similar mechanism of action and primarily target tumor angiogenesis by inhibiting a variety of tyrosine kinases ([@b36-or-38-02-0625],[@b59-or-38-02-0625],[@b60-or-38-02-0625]). Pazopanib is an oral, second-generation multi-targeted tyrosine kinase inhibitor targeting VEGF-1, −2, and −3 receptors, PDGF-α and-β receptors, and c-kit, which exhibited good potency against all of the human VEGFRs and closely related tyrosine receptor kinases *in vitro* ([@b30-or-38-02-0625],[@b31-or-38-02-0625],[@b61-or-38-02-0625]). Besides TKIs, antibodies blocking VEGFR2 have also been developed ([@b62-or-38-02-0625]).

In addition to anti-angiogenesis drugs, there are some other cellular signaling pathways that should be mentioned as they are always used in combination with anti-angiogenesis target drugs in clinical trials of osteosarcoma. A signal transduction pathway through insulin-like growth factor (IGF) receptor signaling, which is also an attractive therapeutic target for the treatment of osteosarcoma, is the mammalian target of the rapamycin (mTOR) pathway ([@b63-or-38-02-0625]). mTOR technically does not belong to anti-angiogenesis therapy according to Hanahan *et al* ([@b64-or-38-02-0625]). Under conditions favorable for cell growth, mTOR activates ribosomal protein translation (via S6K1) and cap-dependent translation (via eIF4E), allowing G~1~ to S phase cell cycle progression. This signal pathway was not originally activated in most sarcoma patients ([@b65-or-38-02-0625]), but after using anti-angiogenesis TKIs for a while, many sarcomas show secondary activated pathway, which makes this target as a supplement to TKIs for long-term use ([@b66-or-38-02-0625]). At the same time, the involvement of the IGF/IGF1-R axis in tumorigenesis makes it an attractive target for anticancer therapeutics, especially in Ewing\'s sarcoma ([@b65-or-38-02-0625]). A human IgG1 type monoclonal antibody directed against the human IGF-IR, has been developed to antagonize IGF-IR signaling ([@b67-or-38-02-0625],[@b68-or-38-02-0625]).

3.. Clinical trials of anti-angiogenesis of osteosarcoma
========================================================

### Current status of second-line chemotherapy for osteosarcoma

After failing standard first-line chemotherapy for osteosarcoma, patients who relapse present a more challenging treatment dilemma. In general, recurrence portends an extremely poor long-term prognosis ([@b1-or-38-02-0625]). In some cases, through aggressive surgical resection of all gross disease, patients can still acquire long-term survival ([@b69-or-38-02-0625],[@b70-or-38-02-0625]). The choice of second-line chemotherapy and the use of investigational drugs are not standardized and the outcomes are dismal ([@b4-or-38-02-0625]). van Maldegem *et al* ([@b2-or-38-02-0625]) carried out a comprehensive analysis of published phase I/II clinical trials between 1990--2010 in osteosarcoma and Ewing\'s sarcoma, and it turned out that the results were not convincing for benefit and most of the time disappointing. From osteosarcoma trials they found only 8% CR, 2.8% PR, and 4% SD. The phase II trials were mainly on second-line chemo-drugs, which contained high-intensity ifosfamide-based therapy with or without autologous peripheral blood stem cell support transplantation, etoposide, topotecan, epirubicin, and even cyclophosphamide. Lagmay *et al* ([@b4-or-38-02-0625]) reviewed the outcome of patients with recurrent osteosarcoma enrolled in 7 phase II trials through Children\'s Cancer Group, Pediatric Oncology Group, and Children\'s Oncology Group and found that in each included trial, the drugs tested were determined to be inactive on the basis of radiographic response rates. The event-free survival for 96 patients with osteosarcoma with measurable disease was 12% at 4 months (95% CI, 6% to 19%), with treatments that included drugs such as docetaxel, topotecan, irinotecan, rebeccamycin, oxaliplatin, xabepilone, and even imatinib, aerosolized granulocyte-macrophage colony-stimulating factor (GM-CSF) from 1997 to 2007 ([@b4-or-38-02-0625]). From these data, we can establish a baseline of the expected time for disease progression in patients with relapsed osteosarcoma.

### Phase I and II trials of target therapy for osteosarcoma

In actual fact, it is difficult to carry out trials in advanced osteosarcoma, mainly because of the problems of recruiting enough eligible patients for the trials. In search of phase I and II anti-angiogenesis trials of osteosarcoma, we identified 35 phase I/II trials for osteogenic sarcoma that were published between 2005 and 2016. Unfortunately, the phase I trials for general sarcoma may not be complete because many trials do not distinguish between different subtypes of osteogenic sarcoma. However, different kinds of sarcomas have totally different biological behaviors, such as osteosarcoma, Ewing\'s sarcoma, and chondrosarcoma, which all originate from bone but show totally different sensitivity to chemo-drugs. Thus, we will just focus on the results of clinical trials that specialized in osteosarcoma so as to make the comparison more meaningful. With an internet search of MEDLINE, the Embase database, the Cochrane Central Register of Controlled Trials database, the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO), we summarize the list of phase I and II trials in [Tables II](#tII-or-38-02-0625){ref-type="table"} and [III](#tIII-or-38-02-0625){ref-type="table"}, which only include the data of osteosarcoma and the clinical results ([@b11-or-38-02-0625]--[@b13-or-38-02-0625],[@b27-or-38-02-0625]--[@b33-or-38-02-0625],[@b35-or-38-02-0625]--[@b39-or-38-02-0625],[@b53-or-38-02-0625],[@b61-or-38-02-0625],[@b67-or-38-02-0625],[@b68-or-38-02-0625],[@b71-or-38-02-0625]--[@b78-or-38-02-0625]).

Abundant active agents had been tested for osteosarcoma patients in a small number for their availability. Geller and Gorlick ([@b44-or-38-02-0625]) proposed the use of HER-2 directed therapy for a subset of patients with osteosarcoma, which in theory was an appealing idea assuming HER-2 expression was in fact associated with poor prognosis, since expression can be accurately and reproducibly identified. However, a phase II clinical trial initiated by Children\'s Oncology Group of trastuzumab, in addition to standard chemotherapy for patients with newly diagnosed metastatic osteosarcoma ([Table III](#tIII-or-38-02-0625){ref-type="table"}), has proven to be without significant difference when compared with the control group (30 months-EFS 32%; 30 months-OS 50%) ([@b53-or-38-02-0625]). From the list of phase I trials ([Table II](#tII-or-38-02-0625){ref-type="table"}), although there is a small number of patients, it seems to us that the EGFR inhibitor and the antibody against type 1 insulin-like growth factor receptor (IGF-IR) did not show similar activity in osteosarcoma as in Ewing\'s sarcoma ([@b67-or-38-02-0625],[@b68-or-38-02-0625],[@b74-or-38-02-0625]).

Most anti-angiogenesis TKIs can only keep the tumor stable rather than make it obviously shrunken, while only cediranib, which is a TKIs targeted particularly towards VEGFR2 (IC~50~ especially low, shown in [Table I](#tI-or-38-02-0625){ref-type="table"}), had 1 refractory osteosarcoma partial response ([@b35-or-38-02-0625]). Another phase I study that combined cediranib with gefitinib showed antitumor activity in patients with advanced solid tumors, including one osteosarcoma patient ([@b37-or-38-02-0625]). Since we could not get detailed information for this osteosarcoma patient, it was not included in [Table II](#tII-or-38-02-0625){ref-type="table"}. The authors also demonstrated changes in VEGF and soluble VEGFR-2 levels following treatment. These initial subgroup results, which were not as responsive as we expected, might lead to many pharmaceutical companies stopping further investigation of their phase II trials for osteosarcoma. This may be why we seem to stagnate after the sorafenib trial reported by Grignani *et al* ([@b12-or-38-02-0625],[@b13-or-38-02-0625]).

As for phase II trials, the greatest progress belonged to Italian Sarcoma Group, which held 2 cohort phase II trials with advanced osteosarcoma patients with an object response rate (ORR) of 14 and 10%, respectively ([@b12-or-38-02-0625],[@b13-or-38-02-0625]). Although the addition of everolimus did not obviously change the response rate, the combination of sorafenib and everolimus significantly prolonged the duration of response from 4 months in sorafenib alone to 5 months, which has been stated to be the best treatment results in the second-line drug therapy history of osteosarcoma. However, this 45% 6-month PFS (combination therapy) was less than the pre-specified threshold of activity (6 month PFS of 50% or greater) to be deemed worthy of a phase III trial. In addition, the toxic effects seemed to be more severe than sorafenib alone ([@b13-or-38-02-0625]). Children\'s Oncology Group (COG) has conducted several phase II trials with cixutumumab ([@b68-or-38-02-0625]), which is the insulin-like growth factor-I receptor (IGF-IR), since preclinical data suggested that inhibition of the IGF-IR might constitute an important therapeutic target in a variety of pediatric solid tumors, including rhabdomyosarcoma, neuroblastoma and Wilms tumor. For refractory solid tumors, there was only a sub-group analysis for osteosarcoma with the number of patients 11 in both the cixutumumab single-drug trial ([@b67-or-38-02-0625]), and in combination with cixutumumab and temsirolimus in a trial ([@b68-or-38-02-0625]). However, for pediatric advanced osteosarcoma, the ORR was 0% for both of the trials. With PFS and OS data unextractable in both of these trials, only 1 patient using cixutumumab alone had stable disease for 140 days ([@b67-or-38-02-0625]). In 2013, Memorial Sloan-Kettering Cancer Center (MSKCC) proceeded with a similar trial with a combination of cixutumumab and temsirolimus on refractory osteosarcoma, which showed an ORR of 13% with a median PFS of 6 weeks ([@b74-or-38-02-0625]). The number of patients was 24, which showed a little more than the same trial conducted by COG of 11 ([@b68-or-38-02-0625]). MSKCC included patients older than 16 years while COG included all solid tumor patients aged from 1--30 years. Due to the small sample size, we could not speculate why their results were so different. This combination therapy may need further study with a larger sample size in a randomized controlled trial to identify its effectiveness. The Sarcoma Alliance for Research Through Collaboration Study has also completed 2 trials on advanced osteosarcoma, which were respectively IGF-IR R1507 and TKI dasatinib ([@b11-or-38-02-0625],[@b77-or-38-02-0625]). R1507 did not seem to be effective with an ORR of 2.5% and 12-week-PFS of 17%, while dasatinib showed an ORR of 6.5% and duration of response of 5.7 months, which indicated that BCR/ABL, c-kit, and src might not be the target for osteosarcoma. The Bayesian design allowed for the early termination of accrual in osteosarcoma subtypes because of the lack of drug activity ([@b11-or-38-02-0625]).

4.. Moving forward, what stops us
=================================

### Resistance

For advanced osteosarcoma patients, drug sensitivity is pivotal at the beginning of therapy to help patients to establish the confidence to continue using it; however, from the observation through phase I trials, these TKIs hardly seemed to reduce the tumor size, which usually stopped investigators to open a phase II trial to explore the activity towards osteosarcoma. From the perspective of Versleijen-Jonkers *et al* ([@b6-or-38-02-0625]), unlike chemotherapeutic agents, angiogenesis inhibitors slow or stop tumor growth rather than cause tumor shrinkage.

Up to now there was no direct evidence on which kind of TKIs have more potency to be sensitive, but we may boldly speculate that cediranib ([@b35-or-38-02-0625]), which is the only drug that made refractory osteosarcoma smaller in size in a phase I trial, might be more sensitive than other TKIs for its low IC~50~ value towards VEGFR, especially VEGFR-2. There is a general consensus that VEGFR-2 is the dominant receptor in mediating the pro-angiogenic functions of VEGF-A, and this pathway has been prioritized for the development of anti-angiogenic therapies ([@b16-or-38-02-0625]). Clinical trial expression analysis of different subtypes of tyrosine kinases as predictive biomarkers is still not a standard approach. Furthermore, only limited studies have investigated the expression of different subtypes of tyrosine kinase receptors on the protein level, especially on osteosarcoma ([@b45-or-38-02-0625]--[@b47-or-38-02-0625],[@b79-or-38-02-0625]--[@b82-or-38-02-0625]). We do not know what kinds of TKIs showed more sensitivity and what kind of TKIs have more long-term lasting effectiveness based on those clinical trials. We may need to focus more on the IC~50~ values of specific subtypes of VEGFR and carry out more detailed work to choose appropriate targets for clinical use.

Twenty-five TKIs are currently FDA-approved and \>130 are being evaluated in clinical trials ([@b14-or-38-02-0625]). Increasing evidence suggests that drug exposure of TKIs may significantly contribute to drug resistance independently of somatic variation of TKI target genes. Membrane transport proteins may limit the amount of TKI reaching the target cells. In the early study of sunitinib on solid tumors, a decrease in the expression level of soluble VEGFR has been consistently reported ([@b83-or-38-02-0625]). Conversely, an increased level of VEGF seems to occur and may have a role in the flare-up of tumor growth that may occur after sunitinib discontinuation ([@b83-or-38-02-0625]). In addition, activation of alternative signaling pathways may overcome VEGFR inhibition. According to Loges *et al* ([@b84-or-38-02-0625]), this reality depends on the mechanisms of refractoriness and evasive escape and the lack of well-validated biomarkers to monitor efficacy as well as optimal dosing or predict toxicity or resistance to VEGF-targeted therapy. Mutation of VEGFR/PDGFR or altered receptors or polymorphisms may also have a role in the resistance to anti-VEGF/VEGFR therapy ([@b85-or-38-02-0625]). The resistance of this peripheral rim of viable tumor cells may be overcome by combination TKIs with targeted agents directed against kinases, such as mTOR, mitogen-activated protein kinases (MAPKs), and protein kinase C (PKC) or the addition of cytotoxic drugs to destroy sub-clones evading multi-targeted agents ([@b65-or-38-02-0625]).

In addition to morphological differences, tumor endothelial cells have distinct gene expression profiles, which may also contribute to the resistance to antiangiogenic treatment strategies ([@b6-or-38-02-0625]). Furthermore, the heterogeneity of cancer has often been a subject of interest and concern. DNA sequencing in a single tumor biopsy of 1 patient was not uniformly detectable throughout the sampling region ([@b86-or-38-02-0625]). Such dynamic genomic changes in cancer cells are also expected to induce resistance in response to anti-angiogenesis drugs ([@b87-or-38-02-0625]). The above explains why sorafenib only has the duration of response of 4 months while a combination with everolimus makes it 5 months ([@b12-or-38-02-0625],[@b13-or-38-02-0625]), which does not yet seems to be satisfactory for advanced patients. From these mechanisms, we can expect that combination therapy or sequencing therapy may benefit more people, which will be discussed later.

### Toxicity

Compared with conventional chemotherapy, the toxicity and side effects of anti-angiogenesis TKIs are mild and can be tolerated by most heavily pre-treated advanced osteosarcoma patients. The most common toxicities are hypertension (grade 3 in approximately 10% patients), hand and foot syndrome, fatigue, proteinuria (usually grade 1--2), hemorrhage, arterial and venous thrombotic events ([@b88-or-38-02-0625]), impaired wound healing, and occasionally gastrointestinal perforation ([@b89-or-38-02-0625]), which was mostly observed in the initial phase II bevacizumab trials in ovarian cancer. VEGFR TKIs have also been associated with clinical hypothyroidism, which could be caused by the inhibition of iodine uptake in the thyroid ([@b90-or-38-02-0625]). Some of those syndromes were reported to be related with better response and can be relieved gradually after months of therapy ([@b88-or-38-02-0625]). However, combination therapy with multiple anti-angiogensis agents were considered to have more severe toxicity than some patients could tolerate ([@b12-or-38-02-0625]). How to manage toxicity and efficiency is still a problem.

### Evaluation systems

In addition to the challenge of identifying the most promising agents for clinical trials in osteosarcoma, obstacles inherent to this disease further complicate the successful design and completion of trials. In evaluating the efficacy of all the trials we have mentioned, the standard approach is to use imaging response criteria, such as response evaluation criteria in solid tumors 1.1 (RECIST 1.1) to compare the size and/or volume of lesion pretreatment and at regular intervals post-treatment ([@b91-or-38-02-0625]). For a patient eligible for a trial using this approach, he or she must have measurable disease. However, as we mentioned before, angiogenesis inhibitors slowed or stopped tumor growth rather than causing the tumor\'s shrinkage ([@b16-or-38-02-0625]).

Referring to most successful TKI therapy examples, such as renal cell carcinoma, GIST, or even soft tissue sarcoma, and considering with the characteristics of anti-angiogenesis TKIs, various new clinical evaluation systems have turned up, such as Choi (2009) ([@b92-or-38-02-0625]), mChoi (2010) ([@b93-or-38-02-0625]), SACT (2010) ([@b94-or-38-02-0625]), and MASS (2010) ([@b94-or-38-02-0625]). Nevertheless we cannot indiscriminately copy this evaluation. Because for unresectable primary osteosarcoma, which is located at the axial skeleton, for example, lesions mainly manifest as a bone lesion combined with or without soft tissue mass, which may not be evaluable according to these criteria. The lesion\'s shrinkage is originally not so obvious as other solid tumors. Besides, osteosarcoma is an osteogenic tumor that should not be evaluated by the M.D. Anderson system ([@b95-or-38-02-0625]), which was developed to evaluate metastatic osteolytic lesions. All the above makes it even more complicated to assess the condition.

There are a few potential biomarkers in the blood that can be used to determine *in vivo* efficacy of anti-angiogenic treatment, i.e., VEGF-A, VEGF-B, and PIGF ([@b96-or-38-02-0625]), circulating endothelial cells ([@b97-or-38-02-0625],[@b98-or-38-02-0625]), and even neutrophil-to-lymphocyte ratio ([@b99-or-38-02-0625]). However, these biomarkers need to be studied further before they can be used in the clinic. In addition, functional imaging might be beneficial for evaluation, such as dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) ([@b100-or-38-02-0625]), positron emission computed tomography (PET/CT) ([@b101-or-38-02-0625]), and so on, which are under study and could make the prediction and monitoring of response more sensitive and ultimately lead to personalized anti-angiogenic treatment.

5.. Strategy for advanced osteosarcoma in the era of targeted therapy
=====================================================================

With the development of precision medicine, tremendous improvement has happened to traditional pathology. From the linking genomic and immunotherapy approaches to molecular subtype theory of Lim *et al* ([@b102-or-38-02-0625]), we got to know that osteosarcoma has a more increased mutation burden than Ewing\'s sarcoma or synovial sarcoma, which is why it has not benefited from comprehensive molecular profiling ([@b103-or-38-02-0625],[@b104-or-38-02-0625]). Gerlinger *et al* ([@b86-or-38-02-0625]) proposed the theory of intratumor heterogeneity and branched evolution of tumor cells in 2012, which made it even more difficult for the targeted therapy to maintain a long-term effect. Facing the intratumor heterogeneity at the genomic, epigenomic, and micro-environmental levels, the question is what is the optimal therapeutic option for these refractory groups.

### Combination therapy, what we can do

The combination of anti-angiogenesis drugs with chemotherapy has been proposed for quite a while and has been verified in clinical trials of osteosarcoma with unfavorable results ([@b53-or-38-02-0625],[@b71-or-38-02-0625]) ([Table III](#tIII-or-38-02-0625){ref-type="table"}). It is a sound deduction that a treatment aimed at reducing the blood supply of a tumor would also reduce the delivery of any other therapy, such as chemotherapy, which is also important for radiotherapy for anti-angiogenesis agents and may reduce the oxygen supply necessary for a response to radiotherapy ([@b16-or-38-02-0625]). However, synergism of anti-angiogenetics and chemotherapeutics has been observed in patients with colon cancers ([@b105-or-38-02-0625]), non-small cell lung cancers ([@b106-or-38-02-0625]), and breast cancers ([@b107-or-38-02-0625],[@b108-or-38-02-0625]). One explanation is that with the blockage of VEGF signaling, anti-angiogenetics induces a normalization of newly formed vessels, and thus, reduces the interstitial tissue pressure (ITP) within tumors, allowing enhanced delivery of chemotherapy to the tumors ([@b7-or-38-02-0625]). However, advanced osteosarcoma usually has shown resistance to conventional chemotherapy. Second-line chemotherapy did not have much of an effect on these tumors, which makes the combination therapy not reasonable.

From the experience of Grignani *et al* ([@b12-or-38-02-0625]), the multi-targeted approach with TKIs or a combination of different pathway inhibitors seemed to have advantages in synergistic therapeutic effect and to overcome drug resistance. A disadvantage of using multi-targeted agents was that it might increase the toxicity and be difficult to determine which particular kinase inhibition results in an antitumor effect. Anyway, the prolonged time seemed not to be long enough to continue with a phase III trial ([@b12-or-38-02-0625]). How to pick the appropriate drugs for combination therapy is still pending.

### Sequencing therapy, timing, and strategy

Sequencing TKI therapy is a new concept for osteosarcoma. However, as for renal cell carcinoma (RCC) ([@b109-or-38-02-0625]) and non-small cell lung cancer ([@b110-or-38-02-0625]), it has been under discussion for a long time. At present, there is a strong rationale for sequencing targeted therapy for metastatic clear cell renal cancer ([@b111-or-38-02-0625]), but the timing of the switch and the best agent to switch to remains unclear. Sunitinib and pazopanib are approved treatments in first-line therapy for patients with favorable or intermediate-risk clear cell RCC ([@b112-or-38-02-0625]). Temsirolimus has been proven to be beneficial over interferon-α (IFN-α) in patients with non-clear cell RCC (non-ccRCC) ([@b113-or-38-02-0625]). Until recently, with regard to choosing the second-line treatment after the failure of therapy with VEGFR-TKIs, the continued inhibition of the VEGF/VEGR pathway or the switch to a mTOR inhibitor was controversial ([@b114-or-38-02-0625]). These two options are characterized by partly different targets with completely different toxicity, but a comparable efficacy. This scenario changed dramatically, after the publication of 2 randomized, controlled, phase III trials, in which cabozantinib ([@b115-or-38-02-0625]) and nivolumab ([@b116-or-38-02-0625]) proved to be superior compared to everolimus. Regarding third-line treatment, where a sequence of 2 VEGFR-TKIs has been used beforehand, the choice is represented by the mTOR inhibitor everolimus, while if a VEGFR-TKI followed by everolimus is chosen, a return to VEGF pathway inhibition is suggested ([@b112-or-38-02-0625]), which indicates the activation of different pathways might change during sequencing therapy and using targeted therapy back and forth may benefit drug-resistance patients and prolong survival. In the perspective of Maute *et al* ([@b117-or-38-02-0625]), possible sequences include TKI-mTOR-TKI or TKI-TKI-mTOR with the upcoming checkpoint inhibitors in perspective, which might establish a new standard of care after previous TKI therapy.

However, for GIST, long-term follow-up results of the B2222 study and updated results of the BFR14 trial demonstrate that continuous imatinib treatment in patients with advanced GIST is associated with reduced risk of progression ([@b118-or-38-02-0625]). For patients progressing on or intolerant of imatinib, continuing therapy with TKIs sunitinib followed by regorafenib is recommended ([@b118-or-38-02-0625]), which seems to us a totally different strategy. For non-small cell lung cancer (NSCLC) therapy, the reversible epidermal growth factor receptor (EGFR) TKIs gefitinib and erlotinib have been proven to be the first-line therapy for NSCLC harboring activating EGFR mutations ([@b119-or-38-02-0625]). Acquired resistance to EGFR TKIs is mainly mediated through 3 pathways: 1) activated EGFR family proteins and ligands, 2) activated various growth factor receptors, and 3) activated downstream signaling molecules ([@b110-or-38-02-0625]). To explore the various proposed mechanisms of acquired resistance to EGFR-TKI therapy, agents that target secondary driving gene mutation as well as signaling pathways downstream of EGFR are being studied in molecularly selected advanced NSCLC ([@b110-or-38-02-0625]), which, in a certain sense, formulates a more logical therapeutic strategy for advanced solid tumors. A degree of cross-resistance appears to exist between all of these current agents and has resulted in a drive toward the development of new therapies with novel modes of action ([@b14-or-38-02-0625]).

6.. Conclusion
==============

For advanced osteosarcoma, due to its increased mutation burden and intratumor heterogeneity, therapy based on comprehensive molecular profiling has not been successfully proven. At present, anti-angiogenesis TKIs showed promising initial results for this group of patients compared to other second-line chemotherapy, but the results are still not satisfactory. Based on the limited options of effective agents, the algorithm of choosing optimal target drugs is still understudied. The anti-angiogenesis TKIs therapy of other solid tumors may shed light on the treatment for advanced OS.

We thank Dr Carola A.S. Arndt of Mayo Clinic Pediatric Oncology for her professional advice for the modification of this study.
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###### 

Summary of the mechanisms of action of the anti-angiogenic compounds in preclinical experiments of osteosarcoma.

  Compound                  Mechanism                                                                                  Target (IC~50~, nM)                                                                                                                                                                       Refs.
  ------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  Endostatin                Internal fragment of the carboxy-terminus of collagen XVIII                                A broad-spectrum endogenous antiangiogenic molecule                                                                                                                                       ([@b62-or-38-02-0625],[@b74-or-38-02-0625])
  MMPs                      A family of enzymes that proteolytically degrade various components of the ECM             Non-specific                                                                                                                                                                              ([@b74-or-38-02-0625])
  PEDF                      A secreted glycoprotein that is a non-inhibitory member of the serine protease inhibitor   Non-specific                                                                                                                                                                              ([@b47-or-38-02-0625]--[@b52-or-38-02-0625],[@b74-or-38-02-0625])
  Bevacizumab               A humanized anti-VEGF antibody                                                             VEGF-A(ED~50~ = 50 ng/ml)                                                                                                                                                                 ([@b31-or-38-02-0625],[@b35-or-38-02-0625],[@b40-or-38-02-0625],[@b98-or-38-02-0625],[@b114-or-38-02-0625]--[@b116-or-38-02-0625])
  Pegaptanib                An anti-VEGF RNA aptamer                                                                   VEGF~165~ (0.75--1.4)                                                                                                                                                                     ([@b66-or-38-02-0625])
  VEGF Trap (Aflibercept)   A soluble receptor to VEGF                                                                 VEGF-A and VEGF-B (0.001), placental growth factor (0.045)                                                                                                                                ([@b67-or-38-02-0625])
  Sorafenib                 TKIs                                                                                       VEGFR-2 ([@b90-or-38-02-0625]), Raf-1 ([@b6-or-38-02-0625]), B-Raf ([@b22-or-38-02-0625]), c-kit ([@b68-or-38-02-0625]), FGFR-1 (580), FLT-3 ([@b58-or-38-02-0625])                       ([@b15-or-38-02-0625],[@b16-or-38-02-0625],[@b35-or-38-02-0625],[@b70-or-38-02-0625],[@b71-or-38-02-0625],[@b86-or-38-02-0625])
  Sunitinib                 TKIs                                                                                       VEGFR-1 ([@b2-or-38-02-0625]), VEGFR-2 ([@b80-or-38-02-0625]), VEGFR-3 ([@b17-or-38-02-0625]), PDGFR-β ([@b2-or-38-02-0625])                                                              ([@b43-or-38-02-0625],[@b45-or-38-02-0625],[@b92-or-38-02-0625])
  Cediranib                 TKIs                                                                                       VEGFR-2 (\<1), VEGFR-1 ([@b5-or-38-02-0625]),                                                                                                                                             ([@b13-or-38-02-0625],[@b42-or-38-02-0625])
  Pazopanib                 TKIs                                                                                       VEGFR-3 (≤3), VEGFR-1 ([@b10-or-38-02-0625]), VEGFR-2 ([@b30-or-38-02-0625]), VEGFR-3 ([@b47-or-38-02-0625]), PDGFR-β ([@b84-or-38-02-0625]), c-kit (140), FGFR ([@b74-or-38-02-0625]),   ([@b37-or-38-02-0625]--[@b39-or-38-02-0625],[@b72-or-38-02-0625])
  Ramucirumab               A fully humanized MAb targeting to the extracellular VEGF-binding domain of VEGFR-2        c-fms (146), VEGFR-2 (0.05)                                                                                                                                                               ([@b73-or-38-02-0625])
  Dasatinib                 TKIs                                                                                       BCR/ABL (\<1), c-kit ([@b79-or-38-02-0625]), Src (0.8)                                                                                                                                    ([@b14-or-38-02-0625])
  Regorafenib               TKIs                                                                                       VEGFR-1 ([@b13-or-38-02-0625]), VEGFR-2 (4.2), VEGFR-3 ([@b46-or-38-02-0625]), PDGFR-β ([@b22-or-38-02-0625]), c-kit ([@b7-or-38-02-0625]), RET (1.5), Raf-1 (2.5)                        ([@b74-or-38-02-0625])
  Everolimus                mTOR signaling pathways                                                                    FKBP12 (1.6--2.4)                                                                                                                                                                         (15,87,124)
  Imatinib                  TKIs                                                                                       v-Abl (600), c-kit ([@b100-or-38-02-0625]), PDGFR ([@b100-or-38-02-0625])                                                                                                                 ([@b54-or-38-02-0625])

IC~50~, median inhibition concentration; concentration that reduces the effect by 50%. MMPs, metalloproteinases; PEDF, pigment epithelium-derived factor; ECM, extracellular matrix; TKIs, tyrosine kinase inhibitors; mTOR, mammalian target of rapamycin.

###### 

Clinical results of phase I trial with currently available anti-angiogenesis therapy on osteosarcoma.

  Drug                      Targets                                               Combined with chemotherapy   The first author\'s surname   Year of publication   Trial sponsor         Clinical results   Refs.
  ------------------------- ----------------------------------------------------- ---------------------------- ----------------------------- --------------------- --------------------- ------------------ ------------------------
  Gefitinib                 EGFR                                                  No                           Daw                           2005                  COG                   6/6 PD             ([@b44-or-38-02-0625])
  Everolimus; Figitumumab   mTOR; IGF-IR                                          No                           Quek                          2010                  Novartis and Pfizer   3/3 SD             ([@b87-or-38-02-0625])
  Cediranib                 VEGFR1-3                                              No                           Fox                           2010                  NIH, NCI              1/4 PR             ([@b42-or-38-02-0625])
  R1507                     IGF-IR                                                No                           Bagatell                      2010                  NIH                   2/3 SD             ([@b46-or-38-02-0625])
  Sunitinib                 VEGFR; PDGFR; c-kit; Flt3, CSF-1 receptor, and RET    No                           Dubios                        2011                  COG                   1/2 SD             ([@b43-or-38-02-0625])
  Cixutumumab               IGF-IR                                                No                           Malempati                     2012                  COG                   3/3 PD             ([@b36-or-38-02-0625])
  Pazopanib                 VEGFR1-3; PDGFR                                       No                           Bender                        2013                  COG                   1/4 SD             ([@b39-or-38-02-0625])
  Sorafenib; Bevacizumab    VEGFR-2, Raf-1, B-Raf, c-kit, FGFR-1, FLT-3; VEGF-A   Low-dose cyclophosphamide    Navid                         2013                  Novartis and Pfizer   2/2 SD             ([@b35-or-38-02-0625])

Clinical responses were defined as described in the referred studies. CBR, clinical benefit response; CR, complete response; PR, partial response; MR, minor response; SD, stable disease (for at least 8 weeks); PD, progressive disease (no response). COG, Children\'s Oncology Group; NIH, National Institutes of Health; NCI, National Cancer Institute; EGFR, epidermal growth factor receptor; mTOR, mammalian target of rapamycin signaling pathways; IGF-IR, type 1 insulin-like growth factor receptor; VEGFR, vascular endothelial growth factor receptor.

###### 

Summary of Phase II trial results of currently available anti-angiogenesis therapy for osteosarcoma.

  Drug                           Combined with chemotherapy   Stage                                    The first author\'s last name   Year of publication   Trial sponsor           No. of patients   Clinical outcome                                                                                   Refs.
  ------------------------------ ---------------------------- ---------------------------------------- ------------------------------- --------------------- ----------------------- ----------------- -------------------------------------------------------------------------------------------------- ------------------------
  Sorafenib                      No                           Advanced                                 Grignani                        2011                  Italian Sarcoma Group   35                4 months-PFS 46%; DR 4 months; ORR 14%                                                             ([@b16-or-38-02-0625])
  Trastuzumab                    Cytotoxic chemotherapy       Newly diagnosed, high-grade metastatic   Ebb                             2012                  COG                     41                30 months-EFS 32%; 30 months-OS 50%; without significant difference comparing with control group   ([@b64-or-38-02-0625])
  Sirolimus                      Cyclo-phosphamide            Advanced                                 Schuetze                        2012                  Michigan University       5               ORR 0%; 4 months-PFS 30% (combined with other sarcoma)                                             ([@b82-or-38-02-0625])
  Cixutumumab and temsirolimus   No                           Advanced                                 Schwartz                        2013                  MSKCC fund              24                ORR 13%; median PFS 6 weeks                                                                        ([@b85-or-38-02-0625])
  Cixutumumab                    No                           Advanced                                 Weigel                          2014                  COG                     11                ORR 0%; 1/11 SD for 140 days                                                                       ([@b36-or-38-02-0625])
  R1507                          No                           Advanced                                 Pappo                           2014                  SARC                    38                ORR 2.5%; DR: 12 weeks; 12 weeks-PFS 17%                                                           ([@b88-or-38-02-0625])
  Sorafenib; Everolimus          No                           Advanced                                 Grignani                        2015                  Italian Sarcoma Group   38                6 months-PFS 45%; DR 5 months; ORR 10%                                                             ([@b15-or-38-02-0625])
  Cixutumumab; Temsirolimus      No                           Advanced                                 Wagner                          2015                  COG                     11                ORR 0%                                                                                             ([@b79-or-38-02-0625])
  Dasatinib                      No                           Advanced                                 Schuetze                        2016                  SARC                    46                ORR 6.5%; DR 5.7 months; 2 years-OS 15%                                                            ([@b14-or-38-02-0625])

PFS, progression-free survival; OS, overall survival; ORR, overall response rate, defined as complete responses (CRs) + partial responses (PRs) + MRs; DR, duration of response; COG, Children\'s Oncology Group; ACS, American Cancer Society; SARC, Sarcoma Alliance for Research Through Collaboration Study; MSKCC, Memorial Sloan-Kettering Cancer Center.
